Rivex Ophthalmics

Rivex Ophthalmics is a clinical-stage biopharmaceutical company focused on developing treatments for acute ocular surface injuries, particularly those resulting from chemical exposure. The company's lead program, RX-101, is a topical formulation designed to mitigate the damage caused by vesicants such as sulfur mustard. Rivex operates primarily through non-dilutive funding from government agencies, including the NIH CounterACT program and BARDA. Their mission is to provide medical countermeasures for both military personnel and civilian populations in the event of chemical accidents or attacks. The company's technology targets specific biochemical pathways to promote corneal healing and prevent long-term vision loss.